-
1
-
-
84908220640
-
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society
-
January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:e1-e76.
-
(2014)
J Am Coll Cardiol
, vol.64
, pp. e1-e76
-
-
January, C.T.1
Wann, L.S.2
Alpert, J.S.3
Calkins, H.4
Cigarroa, J.E.5
Cleveland, J.C.6
Conti, J.B.7
Ellinor, P.T.8
Ezekowitz, M.D.9
Field, M.E.10
Murray, K.T.11
Sacco, R.L.12
Stevenson, W.G.13
Tchou, P.J.14
Tracy, C.M.15
Yancy, C.W.16
-
2
-
-
84994501747
-
2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS
-
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Esquivias BG, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-2962.
-
(2016)
Eur Heart J
, vol.37
, pp. 2893-2962
-
-
Kirchhof, P.1
Benussi, S.2
Kotecha, D.3
Ahlsson, A.4
Atar, D.5
Casadei, B.6
Castella, M.7
Diener, H.C.8
Heidbuchel, H.9
Hendriks, J.10
Hindricks, G.11
Manolis, A.S.12
Oldgren, J.13
Popescu, B.A.14
Schotten, U.15
Van Putte, B.16
Vardas, P.17
Agewall, S.18
Camm, J.19
Esquivias, B.G.20
Budts, W.21
Carerj, S.22
Casselman, F.23
Coca, A.24
De Caterina, R.25
Deftereos, S.26
Dobrev, D.27
Ferro, J.M.28
Filippatos, G.29
Fitzsimons, D.30
Gorenek, B.31
Guenoun, M.32
Hohnloser, S.H.33
Kolh, P.34
Lip, G.Y.35
Manolis, A.36
McMurray, J.37
Ponikowski, P.38
Rosenhek, R.39
Ruschitzka, F.40
Savelieva, I.41
Sharma, S.42
Suwalski, P.43
Tamargo, J.L.44
Taylor, C.J.45
Van Gelder, I.C.46
Voors, A.A.47
Windecker, S.48
Zamorano, J.L.49
Zeppenfeld, K.50
more..
-
3
-
-
0026532168
-
Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter
-
Arnold AZ, Mick MJ, Mazurek RP, Loop FD, Trohman RG. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992;19:851-855.
-
(1992)
J Am Coll Cardiol
, vol.19
, pp. 851-855
-
-
Arnold, A.Z.1
Mick, M.J.2
Mazurek, R.P.3
Loop, F.D.4
Trohman, R.G.5
-
4
-
-
0024539309
-
Anticoagulation for cardioversion of atrial fibrillation
-
Weinberg DM, Mancini J. Anticoagulation for cardioversion of atrial fibrillation. Am J Cardiol 1989;63:745-746.
-
(1989)
Am J Cardiol
, vol.63
, pp. 745-746
-
-
Weinberg, D.M.1
Mancini, J.2
-
5
-
-
84856745317
-
Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and Prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
-
You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GYH. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e531S-e575S.
-
(2012)
Chest
, vol.141
, pp. e531S-e575S
-
-
You, J.J.1
Singer, D.E.2
Howard, P.A.3
Lane, D.A.4
Eckman, M.H.5
Fang, M.C.6
Hylek, E.M.7
Schulman, S.8
Go, A.S.9
Hughes, M.10
Spencer, F.A.11
Manning, W.J.12
Halperin, J.L.13
Lip, G.Y.H.14
-
6
-
-
0014470842
-
The efficacy of anticoagulant therapy in preventing embolism related to D.C. Electrical conversion of atrial fibrillation
-
Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969;23:208-216.
-
(1969)
Am J Cardiol
, vol.23
, pp. 208-216
-
-
Bjerkelund, C.J.1
Orning, O.M.2
-
7
-
-
0035837496
-
Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation
-
Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF; Assessment of Cardioversion Using Transesophageal Echocardiography Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-1420.
-
(2001)
N Engl J Med
, vol.344
, pp. 1411-1420
-
-
Klein, A.L.1
Grimm, R.A.2
Murray, R.D.3
Apperson-Hansen, C.4
Asinger, R.W.5
Black, I.W.6
Davidoff, R.7
Erbel, R.8
Halperin, J.L.9
Orsinelli, D.A.10
Porter, T.R.11
Stoddard, M.F.12
-
8
-
-
78751637313
-
Dabigatran versus warfarin in patients with atrial fibrillation: An analysis of patients undergoing cardioversion
-
Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-136.
-
(2011)
Circulation
, vol.123
, pp. 131-136
-
-
Nagarakanti, R.1
Ezekowitz, M.D.2
Oldgren, J.3
Yang, S.4
Chernick, M.5
Aikens, T.H.6
Flaker, G.7
Brugada, J.8
Kamensky, G.9
Parekh, A.10
Reilly, P.A.11
Yusuf, S.12
Connolly, S.J.13
-
9
-
-
84877276344
-
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial
-
Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Breithardt G; ROCKET AF Steering Committee & Investigators. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013;61:1998-2006.
-
(2013)
J Am Coll Cardiol
, vol.61
, pp. 1998-2006
-
-
Piccini, J.P.1
Stevens, S.R.2
Lokhnygina, Y.3
Patel, M.R.4
Halperin, J.L.5
Singer, D.E.6
Hankey, G.J.7
Hacke, W.8
Becker, R.C.9
Nessel, C.C.10
Mahaffey, K.W.11
Fox, K.A.12
Califf, R.M.13
Breithardt, G.14
-
10
-
-
84896506763
-
Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: Insights from the Aristotle trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation)
-
Flaker G, Lopes RD, Al-Khatib SM, Hermosillo AG, Hohnloser SH, Tinga B, Zhu J, Mohan P, Garcia D, Bartunek J, Vinereanu D, Husted S, Harjola VP, Rosenqvist M, Alexander JH, Granger CB; ARISTOTLE Committees and Investigators. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014;63:1082-1087.
-
(2014)
J Am Coll Cardiol
, vol.63
, pp. 1082-1087
-
-
Flaker, G.1
Lopes, R.D.2
Al-Khatib, S.M.3
Hermosillo, A.G.4
Hohnloser, S.H.5
Tinga, B.6
Zhu, J.7
Mohan, P.8
Garcia, D.9
Bartunek, J.10
Vinereanu, D.11
Husted, S.12
Harjola, V.P.13
Rosenqvist, M.14
Alexander, J.H.15
Granger, C.B.16
-
11
-
-
84976321948
-
Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48
-
Plitt A, Ezekowitz MD, De Caterina R, Nordio F, Peterson N, Giugliano RP. Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48. Clin Cardiol 2016;39:345-346.
-
(2016)
Clin Cardiol
, vol.39
, pp. 345-346
-
-
Plitt, A.1
Ezekowitz, M.D.2
De Caterina, R.3
Nordio, F.4
Peterson, N.5
Giugliano, R.P.6
-
12
-
-
84922418259
-
Rivaroxaban vs. Vitamin K antagonists for cardioversion in atrial fibrillation
-
Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, Hohnloser SH; X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; 35:3346-3355.
-
(2014)
Eur Heart J
, vol.35
, pp. 3346-3355
-
-
Cappato, R.1
Ezekowitz, M.D.2
Klein, A.L.3
Camm, A.J.4
Ma, C.S.5
Le Heuzey, J.Y.6
Talajic, M.7
Scanavacca, M.8
Vardas, P.E.9
Kirchhof, P.10
Hemmrich, M.11
Lanius, V.12
Meng, I.L.13
Wildgoose, P.14
Van Eickels, M.15
Hohnloser, S.H.16
-
13
-
-
84992105111
-
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): A randomised, open-label, phase 3b trial
-
Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GY; ENSURE-AF investigators. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388:1995-2003.
-
(2016)
Lancet
, vol.388
, pp. 1995-2003
-
-
Goette, A.1
Merino, J.L.2
Ezekowitz, M.D.3
Zamoryakhin, D.4
Melino, M.5
Jin, J.6
Mercuri, M.F.7
Grosso, M.A.8
Fernandez, V.9
Al-Saady, N.10
Pelekh, N.11
Merkely, B.12
Zenin, S.13
Kushnir, M.14
Spinar, J.15
Batushkin, V.16
De Groot, J.R.17
Lip, G.Y.18
-
14
-
-
80052825103
-
Apixaban versus warfarin in patients with atrial fibrillation
-
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992.
-
(2011)
N Engl J Med
, vol.365
, pp. 981-992
-
-
Granger, C.B.1
Alexander, J.H.2
McMurray, J.J.3
Lopes, R.D.4
Hylek, E.M.5
Hanna, M.6
Al-Khalidi, H.R.7
Ansell, J.8
Atar, D.9
Avezum, A.10
Bahit, M.C.11
Diaz, R.12
Easton, J.D.13
Ezekowitz, J.A.14
Flaker, G.15
Garcia, D.16
Geraldes, M.17
Gersh, B.J.18
Golitsyn, S.19
Goto, S.20
Hermosillo, A.G.21
Hohnloser, S.H.22
Horowitz, J.23
Mohan, P.24
Jansky, P.25
Lewis, B.S.26
Lopez-Sendon, J.L.27
Pais, P.28
Parkhomenko, A.29
Verheugt, F.W.30
Zhu, J.31
Wallentin, L.32
more..
-
15
-
-
84978173368
-
Apixaban compared with parenteral heparin and/or Vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial
-
Ezekowitz MD, Pollack CV, Sanders P, Halperin JL, Spahr J, Cater N, Petkun W, Breazna A, Kirchhof P, Oldgren J. Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: rationale and design of the EMANATE trial. Am Heart J 2016; 179:59-68.
-
(2016)
Am Heart J
, vol.179
, pp. 59-68
-
-
Ezekowitz, M.D.1
Pollack, C.V.2
Sanders, P.3
Halperin, J.L.4
Spahr, J.5
Cater, N.6
Petkun, W.7
Breazna, A.8
Kirchhof, P.9
Oldgren, J.10
-
16
-
-
85055863521
-
-
Princeton, NJ and New York, NY: Bristol-Myers Squibb and Pfizer; February 2018
-
Eliquis (apixaban) [package insert]. Princeton, NJ and New York, NY: Bristol-Myers Squibb and Pfizer; 2018. https://packageinserts.bms.com/pi/pi_eliquis.pdf (February 2018)
-
(2018)
Eliquis (Apixaban) [Package Insert]
-
-
-
17
-
-
84937681428
-
2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards)
-
Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, Fonarow GC, Jacobs JP, Jaff MR, Lichtman JH, Limacher MC, Mahaffey KW, Mehran R, Nissen SE, Smith EE, Targum SL. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol 2015;66:403-469.
-
(2015)
J Am Coll Cardiol
, vol.66
, pp. 403-469
-
-
Hicks, K.A.1
Tcheng, J.E.2
Bozkurt, B.3
Chaitman, B.R.4
Cutlip, D.E.5
Farb, A.6
Fonarow, G.C.7
Jacobs, J.P.8
Jaff, M.R.9
Lichtman, J.H.10
Limacher, M.C.11
Mahaffey, K.W.12
Mehran, R.13
Nissen, S.E.14
Smith, E.E.15
Targum, S.L.16
-
18
-
-
84879894202
-
An updated definition of stroke for the 21st century: A statement for healthcare professionals from the American Heart Association/ American Stroke Association
-
American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease
-
Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, Elkind MS, George MG, Hamdan AD, Higashida RT, Hoh BL, Janis LS, Kase CS, Kleindorfer DO, Lee JM, Moseley ME, Peterson ED, Turan TN, Valderrama AL, Vinters HV; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke 2013;44:2064-2089.
-
(2013)
Stroke
, vol.44
, pp. 2064-2089
-
-
Sacco, R.L.1
Kasner, S.E.2
Broderick, J.P.3
Caplan, L.R.4
Connors, J.J.5
Culebras, A.6
Elkind, M.S.7
George, M.G.8
Hamdan, A.D.9
Higashida, R.T.10
Hoh, B.L.11
Janis, L.S.12
Kase, C.S.13
Kleindorfer, D.O.14
Lee, J.M.15
Moseley, M.E.16
Peterson, E.D.17
Turan, T.N.18
Valderrama, A.L.19
Vinters, H.V.20
more..
-
19
-
-
23044505564
-
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
-
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-694.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 692-694
-
-
Schulman, S.1
Kearon, C.2
-
20
-
-
84946543850
-
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH
-
Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015;13:2119-2126.
-
(2015)
J Thromb Haemost
, vol.13
, pp. 2119-2126
-
-
Kaatz, S.1
Ahmad, D.2
Spyropoulos, A.C.3
Schulman, S.4
-
21
-
-
84973324735
-
Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF)
-
Lip GYH, Hammerstingl C, Marin F, Cappato R, Ling Meng I, Kirsch B, van Eickels M, Cohen A; On Behalf of the X-TRA study and CLOT-AF registry investigators. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J 2016;178: 126-134.
-
(2016)
Am Heart J
, vol.178
, pp. 126-134
-
-
Lip, G.Y.H.1
Hammerstingl, C.2
Marin, F.3
Cappato, R.4
Ling Meng, I.5
Kirsch, B.6
Van Eickels, M.7
Cohen, A.8
|